<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Betaxolol (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Betaxolol (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Betaxolol (systemic): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11159" href="/d/html/11159.html" rel="external">see "Betaxolol (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F7995918"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antihypertensive;</li>
<li>
                        Beta-Blocker, Beta-1 Selective</li></ul></div>
<div class="block doa drugH1Div" id="F7996038"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>
<b>: </b>Not recommended in the absence of specific comorbidities (eg, ischemic heart disease, arrhythmia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 to 10 mg once daily; titrate as needed after 7 to 14 days based on patient response up to 20 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991816"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;">Severe impairment: Initial dose: 5 mg once daily; may increase every 2 weeks up to a maximum of 20 mg once daily</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Hemodialysis: Initial dose: 5 mg once daily; may increase every 2 weeks up to a maximum of 20 mg once daily. Supplemental dose not required.</p></div>
<div class="block doha drugH1Div" id="F50989095"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Dosage adjustments are not routinely required. </p></div>
<div class="block doe drugH1Div" id="F7996039"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b> Oral: Initial: 5 mg once daily</p></div>
<div class="block adr drugH1Div" id="F7995968"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (6% to 8%; symptomatic bradycardia: ≤2%), cold extremity (2%), edema (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (2%), dyspepsia (4% to 5%), nausea (2% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Positive ANA titer (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (1%), fatigue (3% to 10%), insomnia (1% to 5%), lethargy (3%), paresthesia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (3% to 5%), musculoskeletal chest pain (2% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (2%), pharyngitis (2%), rhinitis (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Nervous system: Depression, nervousness</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Nervous system: Dizziness, headache</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, angina pectoris, atrioventricular block, cardiac arrhythmia, flushing, heart failure, hypertension, hypotension, intermittent claudication, peripheral ischemia, syncope, thrombophlebitis, thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, diaphoresis, eczema, erythematous rash, hypertrichosis, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Acidosis, decreased libido, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperkalemia, hyperlipidemia, hyperuricemia, hypokalemia, increased lactate dehydrogenase, increased thirst, menstrual disease, weight gain, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia, anorexia, constipation, dysgeusia, dysphagia, increased appetite, oral mucosa ulcer, rectal disease, salivation, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Altered micturition, breast fibroadenosis, cystitis, dysuria, mastalgia, oliguria, Peyronie disease, prostatitis, proteinuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, leukocytosis, lymphadenopathy, purpuric disease, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Amnesia, ataxia, cerebrovascular disease, changes in thinking, confusion, emotional lability, hallucination, lack of concentration, malaise, neuralgia, neuropathy, numbness, pain, rigors, speech disturbance, stupor, tremor, twitching</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthropathy, lower limb cramp, muscle cramps, neck pain, tendinopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Abnormal lacrimation, blepharitis, cataract, conjunctivitis, dry eye syndrome, iritis, scotoma, subconjunctival hemorrhage, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness, labyrinth disease, otalgia, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Kidney impairment, renal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis, bronchospasm, cough, epistaxis, pneumonia, sinusitis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F7995965"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to betaxolol or any component of the formulation; sinus bradycardia; heart block greater than first-degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; uncompensated cardiac failure</p></div>
<div class="block war drugH1Div" id="F7995966"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse events:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; however, betaxolol, with B<sub>1</sub> selectivity, may be used cautiously with the lowest possible dose (eg, 5 to 10 mg/day), availability of a bronchodilator, and close monitoring; if a dosage increase is indicated, administer in divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cerebrovascular insufficiency: Use with caution in patients with cerebrovascular insufficiency; hypotension and decreased heart rate may reduce cerebral blood flow.</p>
<p style="text-indent:-2em;margin-left:4em;">• Conduction abnormality: Consider preexisting conditions such as sick sinus syndrome before initiating therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; may potentiate and/or mask signs and symptoms of hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure (HF): Use with caution in patients with compensated heart failure and monitor for a worsening of the condition. There is limited data evaluating the efficacy of betaxolol in HF; use is not recommended (AHA/ACC/HFSA [Heidenreich 2022]; Figulla HR 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis; may potentiate myasthenia-related muscle weakness, including diplopia and ptosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral vascular disease (PVD) and Raynaud disease: May precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud disease. Use with caution and monitor for progression of arterial obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prinzmetal variant angina: Beta-blockers without alpha1-adrenergic receptor blocking activity should be avoided in patients with Prinzmetal variant angina since unopposed alpha1-adrenergic receptors mediate coronary vasoconstriction and can worsen anginal symptoms (Mayer 1998).</p>
<p style="text-indent:-2em;margin-left:4em;">• Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis but cause and effect has not been firmly established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in severe impairment and in patients on dialysis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may precipitate thyroid storm.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, ischemia, and/or angina exacerbation. Severe exacerbation of angina, ventricular arrhythmias, and MI have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.</p></div>
<div class="block foc drugH1Div" id="F7996084"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg</p></div>
<div class="block geq drugH1Div" id="F7995916"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F7996086"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Betaxolol HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $1.23 - $1.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $1.86 - $2.67</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F7996048"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Absorption is not affected by food.</p></div>
<div class="block use drugH1Div" id="F7995941"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b> Management of hypertension. <b>Note:</b> Beta-blockers are <b>not</b> recommended as first-line therapy (ACC/AHA [Whelton 2018]).</p></div>
<div class="block mst drugH1Div" id="F7995910"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Betaxolol may be confused with bethanechol, labetalol</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F7995993"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2D6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F7995994"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Beta-Blockers (Beta1 Selective) may enhance the hypoglycemic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: Beta-Blockers may enhance the adverse/toxic effect of Cannabis. Specifically, the risk of hypoglycemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOBUTamine: Beta-Blockers may diminish the therapeutic effect of DOBUTamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose. Increase monitoring for clinical response and adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Systemic): Beta-Blockers may diminish the therapeutic effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Nasal): Beta-Blockers (Beta1 Selective) may diminish the therapeutic effect of EPINEPHrine (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Oral Inhalation): Beta-Blockers (Beta1 Selective) may diminish the therapeutic effect of EPINEPHrine (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epinephrine (Racemic): Beta-Blockers (Beta1 Selective) may diminish the therapeutic effect of Epinephrine (Racemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Systemic): Beta-Blockers (Beta1 Selective) may diminish the therapeutic effect of EPINEPHrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may diminish the therapeutic effect of Etilefrine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etofylline: Beta-Blockers may diminish the therapeutic effect of Etofylline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grass Pollen Allergen Extract (5 Grass Extract): Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine.  Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers.  Management: Consider alternatives to either grass pollen allergen extract (5 grass extract) or beta-blockers in patients with indications for both agents.  Canadian product labeling specifically lists this combination as contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoproterenol: Beta-Blockers may diminish the therapeutic effect of Isoproterenol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: Beta-Blockers may enhance the adverse/toxic effect of Mavacamten. Specifically, negative inotropic effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Beta-Blockers may enhance the therapeutic effect of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: May enhance the therapeutic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reserpine: May enhance the bradycardic effect of Beta-Blockers. Reserpine may enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: May enhance the bradycardic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Beta-Blockers may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: Beta-Blockers may diminish the therapeutic effect of Tasimelteon.  Management: Consider avoiding nighttime administration of beta-blockers during tasimelteon therapy due to the potential for reduced tasimelteon efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">White Birch Allergen Extract: Beta-Blockers may enhance the adverse/toxic effect of White Birch Allergen Extract. Specifically, beta-blockers may reduce the effectiveness of beta-agonists that may be required to treat systemic reactions to white birch allergen extract. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F58482018"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be used in patients trying to conceive. Betaxolol is not considered a preferred agent for use in pregnant patients; consider transitioning to a preferred agent in patients planning to become pregnant (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Impotence is noted in product labeling following use of betaxolol. As a class, outcomes from available studies evaluating beta-blockers and sexual dysfunction are inconsistent, and the negative effects on erectile function are considered controversial. A clear relationship between use of beta-blockers and erectile dysfunction has not been established. Hypertension itself is associated with erectile dysfunction. Patients on a beta-blocker presenting with sexual dysfunction should be evaluated for underlying disease (Farmakis 2022; Levine 2012; Semet 2017; Terentes-Printzios 2022; Viigimaa 2020).</p></div>
<div class="block pri drugH1Div" id="F7995963"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Betaxolol crosses the placenta (Morselli 1990).</p>
<p style="text-indent:0em;margin-top:2em;">Following maternal use of betaxolol, the beta-blocker effects may persist in the neonate for several days after birth. The risk of cardiac and pulmonary complications is increased in the neonate. Bradycardia, hypoglycemia, and respiratory distress have been reported and monitoring of the neonate for 3 to 5 days after birth is recommended.</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is also associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Based on available data, pregnancy-induced physiologic changes do not alter the pharmacokinetic properties of betaxolol. The maternal half-life and serum concentration of betaxolol immediately postpartum are not significantly different than what is observed in nonpregnant patients (Boutroy 1990; Morselli 1990).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of hypertension is initiated during pregnancy, agents other than betaxolol may be preferred (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018], SOGC [Magee 2022]).</p></div>
<div class="block brc drugH1Div" id="F10546209"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Betaxolol is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of betaxolol in breast milk are available from 3 mothers who were part of a larger pharmacokinetic study of betaxolol during pregnancy. In the first case, betaxolol 10 mg was administered as a single dose 3 hours prior to delivery; breast milk concentrations ranged from 48 ng/mL at 24 hours to 3 ng/mL 72 hours postpartum. In the second case, the mother had received 2 doses of betaxolol 10 mg (last dose 26 prior to delivery); breast milk concentrations were 7.8 ng/mL and 4.2 ng/mL, 24 and 48 hours postpartum, respectively. The third mother also received 2 doses of betaxolol 10 mg (last dose 25 hours prior to delivery); breast milk concentrations were 8.8 ng/mL 48 hours postpartum and 7 ng/mL postpartum (Morselli 1990). According to the manufacturer, betaxolol may be present in amounts that could have a pharmacologic effect in the breastfeeding infant.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that caution be exercised when administering betaxolol to breastfeeding patients. Use of a beta-blocker other than betaxolol may be preferred in lactating patients (ESC [Cífková 2020]).</p></div>
<div class="block mop drugH1Div" id="F7996050"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure, heart rate; kidney function; signs and symptoms of bronchospasm in patients with existing bronchospastic disease; serum glucose (in patients with diabetes).</p></div>
<div class="block rer drugH1Div" id="F57875368"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Blood pressure goal<b>:</b> May vary depending on clinical conditions, different clinical practice guidelines, and expert opinion. Refer to "Clinical Practice Guidelines" for specific treatment goals.</p></div>
<div class="block pha drugH1Div" id="F7996023"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competitively blocks beta<sub>1</sub>-receptors, with little or no effect on beta<sub>2</sub>-receptors</p></div>
<div class="block phk drugH1Div" id="F7996025"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: 1 to 1.5 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: ~100%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic to multiple metabolites</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~50%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: 89%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 14 to 22 hours; prolonged in hepatic disease and/or chronic renal failure. In patients with chronic renal failure undergoing dialysis, the half-life and AUC are approximately doubled.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: 1.5 to 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (&gt;80%, as unchanged drug [15%] and inactive metabolites)</p></div>
<div class="block phksp drugH1Div" id="F51153989"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Elimination may be decreased.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961958"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Kerlone</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Betac</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Kerlone</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Betamed | Betaxa | Betaxolol | Betaxolol medreg | Betaxolol pmcs | Kerlone | Lokren</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Kerlone</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Betaxolol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Kerlon</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Betaxolol biogaran | Betaxolol Dci | Betaxolol eg | Betaxolol mylan | Betaxolol sandoz | Betaxolol teva | Kerlone</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Kerlone</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Kerlone | Pertaxol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Kerlone</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Lokren</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Kerlone mite</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Kerlon</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Betac | Kerlone</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Along | Betakyl | Betakyl sawai | Kefnan | Kerlong | Tarlong</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Betac | Daberol | Hifree | Kerlone</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Kerlone</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Betac | Betaxolol pmcs | Lokren</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Kerlone</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Betac | Betaxolol pmcs | Lokren</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Kerlone</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Betac | Kerlone</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Kerlon</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Betac | Kerlone</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Betaxolol pmcs | Betaxomyl | Lokren</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Betaxolol | Betaxolol HCL | Kerlone</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Kerlone</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Betac | Lokren</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Betac | Betaxolol | Lokren</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Kerlone</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Kerlone</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Betac | Betaxolol medreg | Betaxolol mylan | Lokren</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Kerlone | Ketaxol | Keval</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Betac | Betarun | Bexolo | Kerlone</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Betac | Lokren</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50. doi:10.1097/AOG.0000000000003020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference">
                  Betaxolol tablet [package label]. Franklin, KY: PuraCap Laboratories, LLC; December 2016.</div>
</li>
<li>
<div class="reference">
                  Betaxolol tablet [prescribing information]. Franklin, KY: PuraCap Laboratories, LLC; August 2016.</div>
</li>
<li>
<div class="reference">
                  Betaxolol tablet [prescribing information]. Newtown, PA: KVK Tech Inc; December 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1973651">
<a name="1973651"></a>Boutroy MJ, Morselli PL, Bianchetti G, et al, "Betaxolol: A Pilot Study of Its Pharmacological and Therapeutic Properties in Pregnancy," <i>Eur J Clin Pharmacol</i>, 1990, 38(6):535-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/1973651/pubmed" id="1973651" target="_blank">1973651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18410416">
<a name="18410416"></a>Brauchli YB, Jick SS, Curtin F, et al, “Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,” <i>Br J Dermatol</i>, 2008, 158(6):1299-307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/18410416/pubmed" id="18410416" target="_blank">18410416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11937178">
<a name="11937178"></a>Dahlof B, Devereux RB, Kjeldsen SE, et al; Life Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. <i>Lancet</i>. 2002;359(9311):995-1003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/11937178/pubmed" id="11937178" target="_blank">11937178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33945044">
<a name="33945044"></a>Farmakis IT, Pyrgidis N, Doundoulakis I, Mykoniatis I, Akrivos E, Giannakoulas G. Effects of major antihypertensive drug classes on erectile function: a network neta-analysis. <i>Cardiovasc Drugs Ther</i>. 2022;36(5):903-914. doi:10.1007/s10557-021-07197-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/33945044/pubmed" id="33945044" target="_blank">33945044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16157399">
<a name="16157399"></a>Figulla HR, Krzeminska-Pakula M, Wrabec K, Chochola J,et al. Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III: result of a randomized multicenter trial (BETACAR Trial). <i>Int J Cardiol</i>. 2006;113(2):153-160. doi: 10.1016/j.ijcard.2005.06.067.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/16157399/pubmed" id="16157399" target="_blank">16157399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al, “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,” <i>Circulation</i>, 2012, 126(25):3097-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8296748">
<a name="8296748"></a>Glasser SP, Friedman R, Talibi T, Smith LK, Weir EK. Safety and compatibility of betaxolol hydrochloride combined with diltiazem or nifedipine therapy in stable angina pectoris.<i> Am J Cardiol</i>. 1994;73(4):213-218.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/8296748 /pubmed" id="8296748 " target="_blank">8296748 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064599">
<a name="22064599"></a>Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2011;124(23):e652-735. Erratum in <i>Circulation</i>. 2011;124(25):e957.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/22064599/pubmed" id="22064599" target="_blank">22064599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19372098">
<a name="19372098"></a>Iliuta L, Christodorescu R, Filpescu D, Moldovan H, Radulescu B, Vasile R. Prevention of perioperative atrial fibrillation with betablockers in coronary surgery: betaxolol versus metoprolol. <i>Interact Cardiovasc Thorac Surg</i>. 2009;9(1):89-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/19372098 /pubmed" id="19372098 " target="_blank">19372098 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2014;130(23):e199-e267. doi: 10.1161/CIR.0000000000000041.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16793810">
<a name="16793810"></a>Juul AB, Wetterslev J, Gluud C, et al, “Effect of Perioperative Beta Blockade in Patients With Diabetes Undergoing Major Non-Cardiac Surgery: Randomized Placebo Controlled, Blinded Multicentre Trial. DIPOM Trial Group,” <i>BMJ</i>, 2006, 332(7556):1482.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/16793810/pubmed" id="16793810" target="_blank">16793810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17580734">
<a name="17580734"></a>Kardas P. Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial. <i>Vasc Health Risk Manag</i>. 2007;3(2):235-242.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/17580734 /pubmed" id="17580734 " target="_blank">17580734 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7801876">
<a name="7801876"></a>Koh KK, Kwon KS, Park HB, et al. Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. <i>Am J Cardiol</i>. 1995;75(1):88-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/7801876/pubmed" id="7801876" target="_blank">7801876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7669259">
<a name="7669259"></a>Lang DM, “Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,” <i>Drug Saf</i>, 1995, 12(5):299-304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/7669259/pubmed" id="7669259" target="_blank">7669259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22267844">
<a name="22267844"></a>Levine GN, Steinke EE, Bakaeen FG, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Quality of Care and Outcomes Research. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2012;125(8):1058-1072. doi:10.1161/CIR.0b013e3182447787<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/22267844/pubmed" id="22267844" target="_blank">22267844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9562933">
<a name="9562933"></a>Mayer S, Hillis LD. Prinzmetal's variant angina. <i>Clin Cardiol</i>. 1998;21(4):243-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/9562933/pubmed" id="9562933" target="_blank">9562933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2379532">
<a name="2379532"></a>Morselli PL, Boutroy MJ, Bianchetti G, et al, "Placental Transfer and Perinatal Pharmacokinetics of Betaxolol," <i>Eur J Clin Pharmacol</i>, 1990, 38(5):477-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/2379532/pubmed" id="2379532" target="_blank">2379532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481]. <i>Circulation</i>. 2013;127(4):e362-e425. doi: 10.1161/CIR.0b013e3182742cf6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16210252">
<a name="16210252"></a>Redelmeier D, Scales D, and Kopp A, "Beta Blockers for Elective Surgery in Elderly Patients: Population Based, Retrospective Cohort Study," <i>BMJ</i>, 2005, 331(7522):932.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/16210252/pubmed" id="16210252" target="_blank">16210252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al; American Heart Association; American College of Cardiology; and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15872205">
<a name="15872205"></a>Schön MP and Boehncke WH, “Psoriasis,” <i>N Eng J Med</i>, 2005, 352(18):1899-1912.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/15872205/pubmed" id="15872205" target="_blank">15872205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28622464">
<a name="28622464"></a>Semet M, Paci M, Saïas-Magnan J, et al. The impact of drugs on male fertility: a review. <i>Andrology</i>. 2017;5(4):640-663. doi:10.1111/andr.12366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/28622464/pubmed" id="28622464" target="_blank">28622464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22052934">
<a name="22052934"></a>Smith SC Jr, Benjamin EJ, Bonow RO, et al, “AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,” <i>Circulation</i>, 2011, 124(22):2458-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/22052934/pubmed" id="22052934" target="_blank">22052934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34331033">
<a name="34331033"></a>Terentes-Printzios D, Ioakeimidis N, Rokkas K, Vlachopoulos C. Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. <i>Nat Rev Cardiol</i>. 2022;19(1):59-74. doi:10.1038/s41569-021-00593-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/34331033/pubmed" id="34331033" target="_blank">34331033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32073535">
<a name="32073535"></a>Viigimaa M, Vlachopoulos C, Doumas M, et al; European Society of Hypertension Working Group on Sexual Dysfunction. Update of the position paper on arterial hypertension and erectile dysfunction. <i>J Hypertens</i>. 2020;38(7):1220-1234. doi:10.1097/HJH.0000000000002382<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/32073535/pubmed" id="32073535" target="_blank">32073535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. <i>Hypertension</i>. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wong.1">
<a name="Wong.1"></a>Wong DG, Spence JD, Lamki L, et al, “Effect of Nonsteroidal Anti-inflammatory Drugs on Control of Hypertension of Beta-Blockers and Diuretics,” <i>Lancet</i>, 1986, 1(8488):997-1001.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9732338">
<a name="9732338"></a>UK Prospective Diabetes Study Group, “Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39,” <i>BMJ</i>, 1998, 317(7160):713-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/9732338/pubmed" id="9732338" target="_blank">9732338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17070177">
<a name="17070177"></a>Yang H, Raymer K, Butler R, et al, “The Effects of Perioperative Beta-Blockade: Results of the Metoprolol After Vascular Surgery (MaVS) Study, a Randomized Controlled Trial,” <i>Am Hear J</i>, 2006, 152(5):983-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betaxolol-systemic-drug-information/abstract-text/17070177/pubmed" id="17070177" target="_blank">17070177</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8976 Version 298.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
